Immunotherapy, particularly programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, has been responsible for changing the natural history of advanced or metastatic non-small cell lung cancer. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.